The present application seeks funding to establish an Intellectual and Developmental Disabilities Research Center (IDDRC) at the University of California, which will be fully integrated into, and benefit from, the existing resources of the UC Davis MIND Institute and its campus partners. The MIND Institute is an integrated program that is internationally recognized for ground-breaking studies of autism, fragile X syndrome, and other IDD conditions. The proposed IDDRC includes three components. First, we propose a research component that addresses the focus area of Multi-Modal Treatment Approaches. This component includes a clinical trial targeting children with fragile X syndrome that combines a drug (lovastatin) with a parent-implemented intervention. Novel outcome measures focusing on language and challenging behavior will evaluate efficacy. The clinical trial will be accompanied by studies focused on FMRI-related signaling pathways so as to illuminate the mechanisms by which treatment achieves its effects and to identify biomarkers that indicate treatment efficacy and individual differences in response to treatment. Second, we propose for inclusion 56 IDD-related projects funded by NIH and other federal and private sources. Ten of the projects are funded by NICHD. These projects address three scientific themes: Integrated Biobehavioral Characterization of IDD, Environmental Contributions to IDD, and Treatments for IDD. Third, we propose core components to facilitate interdisciplinary, translational research in IDD. The cores include an Administrative Core and a Clinical Translational Core, with the latter focused on recruitment and diagnostic characterization of human participants. The remaining cores will provide assays of immune function, cellular and molecular biology and imaging, and environmental contaminants (Biological Analysis Core);measures of complex human behavior, particularly for establishing endophenotypes (Neurobehavioral Analysis Core);assays of rodent behavior for evaluating mutant rodent models and supporting preclinical evaluations of drug safety and efficacy (Rodent Behavior Core);and the management and analysis of complex multidimensional data derived from human and animal studies (Biostatistics, Bioinformatics, and Research Design).

Public Health Relevance

The proposed IDDRC is designed to support a translational science agenda focused on IDD. The IDDRC will integrate research from multiple disciplines and bridge basic and clinical science to arrive at treatments for IDD conditions. The range of IDD conditions include autism spectrum disorder, fragile X syndrome, Down syndrome, ADHD, chromosome 22q11.2 deletion syndrome, and many others.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HD079125-02
Application #
8740539
Study Section
Special Emphasis Panel (ZHD1-DSR-H (50))
Program Officer
Parisi, Melissa
Project Start
2013-09-24
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$1,246,354
Indirect Cost
$437,033
Name
University of California Davis
Department
Psychiatry
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Kerin, Tara; Volk, Heather; Li, Weiyan et al. (2018) Association Between Air Pollution Exposure, Cognitive and Adaptive Function, and ASD Severity Among Children with Autism Spectrum Disorder. J Autism Dev Disord 48:137-150
Ozonoff, Sally; Li, Deana; Deprey, Lesley et al. (2018) Reliability of parent recall of symptom onset and timing in autism spectrum disorder. Autism 22:891-896
Benyakorn, Songpoom; Calub, Catrina A; Riley, Steven J et al. (2018) Computerized Cognitive Training in Children With Autism and Intellectual Disabilities: Feasibility and Satisfaction Study. JMIR Ment Health 5:e40
Weir, R K; Bauman, M D; Jacobs, B et al. (2018) Protracted dendritic growth in the typically developing human amygdala and increased spine density in young ASD brains. J Comp Neurol 526:262-274
Edmiston, Elizabeth; Jones, Karen L; Vu, Tam et al. (2018) Identification of the antigenic epitopes of maternal autoantibodies in autism spectrum disorders. Brain Behav Immun 69:399-407
Gangi, Devon N; Schwichtenberg, A J; Iosif, Ana-Maria et al. (2018) Gaze to faces across interactive contexts in infants at heightened risk for autism. Autism 22:763-768
Shen, Mark D; Nordahl, Christine W; Li, Deana D et al. (2018) Extra-axial cerebrospinal fluid in high-risk and normal-risk children with autism aged 2-4 years: a case-control study. Lancet Psychiatry 5:895-904
Pyles, Benjamin; Bailus, Barbara J; O'Geen, Henriette et al. (2018) Purified Protein Delivery to Activate an Epigenetically Silenced Allele in Mouse Brain. Methods Mol Biol 1767:227-239
CastaƱeda, Alejandro R; Pinkerton, Kent E; Bein, Keith J et al. (2018) Ambient particulate matter activates the aryl hydrocarbon receptor in dendritic cells and enhances Th17 polarization. Toxicol Lett 292:85-96
Napoli, Eleonora; Schneider, Andrea; Wang, Jun Yi et al. (2018) Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. Mol Neurobiol :

Showing the most recent 10 out of 175 publications